Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells.

Ribechini E, Leenen PJ, Lutz MB.

Eur J Immunol. 2009 Dec;39(12):3538-51. doi: 10.1002/eji.200939530.

2.

Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control.

Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W.

Eur J Immunol. 2009 Oct;39(10):2809-21. doi: 10.1002/eji.200939389.

3.

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A.

Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712.

4.

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711.

5.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ.

Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30.

6.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE; Children's Oncology Group.

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095.

PMID:
18235123
7.

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.

Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ.

Clin Cancer Res. 2007 Oct 15;13(20):6168-74.

8.
9.

CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.

Murad YM, Clay TM, Lyerly HK, Morse MA.

Expert Opin Biol Ther. 2007 Aug;7(8):1257-66. Review.

PMID:
17696823
10.

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.

Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX.

Cancer Immunol Immunother. 2007 Oct;56(10):1597-604. Epub 2007 Apr 18.

PMID:
17440723
11.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
12.

Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.

Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL.

Immunology. 2007 Mar;120(3):412-23. Epub 2006 Dec 8.

13.

Role of tumor-associated macrophages in tumor progression and invasion.

Mantovani A, Schioppa T, Porta C, Allavena P, Sica A.

Cancer Metastasis Rev. 2006 Sep;25(3):315-22. Review.

PMID:
16967326
14.

Chemotherapy advances in small cell lung cancer.

Rosti G, Carminati O, Monti M, Tamberi S, Marangolo M.

Ann Oncol. 2006 May;17 Suppl 5:v99-102. Review. No abstract available. Erratum in: Ann Oncol. 2012 Aug;23(8):2209.

PMID:
16807475
15.

In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.

Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

J Leukoc Biol. 2006 Jun;79(6):1181-92. Epub 2006 Mar 24.

PMID:
16565324
16.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP.

Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review.

PMID:
16529542
17.

Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.

Dang CT.

Expert Rev Anticancer Ther. 2006 Mar;6(3):427-36. Review.

PMID:
16503859
19.

Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.

Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL.

J Immunol. 2006 Jan 1;176(1):309-18.

20.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

Supplemental Content

Support Center